REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewsCentre/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that, in its patent litigation against Boston Scientific, the parties agreed to the dismissal of the patent case filed by Nevro in the Northern District of California relating to high frequency paresthesia-free SCS therapy. The official dismissal of the case is subject to the approval of the court.
In July 2018, on the basis of the statements made by Boston Scientific to the California court, in which it assured the court that it did not have any imminent plans to commercially launch a high frequency spinal cord stimulation system delivering therapy at frequencies between 1.5 kHz and 100 kHz, the parties agreed to dismissal of Nevro’s declaratory judgment claims. Nevro then proceeded to appeal the California court’s ruling of invalidity, with regard to certain of Nevro’s claims, to the U.S. Court of Appeals for the Federal Circuit. In April 2020, the Federal Circuit issued a ruling in Nevro’s favor, and vacated and remanded the California court’s judgment of invalidity. Because Boston Scientific still does not have any current plans to commercially launch a high frequency SCS system in the United States, the parties agreed to dismiss all remaining claims in the California case.
The parties will continue their ongoing patent cases in the District of Delaware and at the Patent Office relating to patents for other spinal cord stimulation technologies unrelated to high frequency therapy.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in â‰¥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro’s proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
Investors and Media:
Julie Dewey, IRC
Vice President, Investor Relations & Corp Communications
650-433-3247 | firstname.lastname@example.org
SOURCE: Nevro Corp.